je.st
news
Tag: isis pharmaceuticals
Isis Pharmaceuticals changes name to Ionis
2015-12-18 18:21:18| Biotech - Topix.net
Isis Pharmaceuticals, which shares a name with the Islamic State extremist group, has changed its name to Ionis Pharmaceuticals after resisting to do so for some time. The drug developer says its old name was a distraction since it was associated with the Islamic State, which is commonly known by its acronym ISIS.
Tags: to
pharmaceuticals
isis
isis pharmaceuticals
Paris attack prompts name holdout Isis Pharmaceuticals to finally rebrand
2015-11-19 00:43:32| Biotech - Topix.net
The terrorist attacks in Paris may have finally spurred a brand change for Isis Pharmaceuticals Inc., a drugmaker that until now has steadfastly held on to its name even as the militant group rose in prominence in the Middle East. "We want the story to be about the medicines that we're creating, and not about our name," D. Wade Walke, a spokesman for the drugmaker, said in an interview on Wednesday.
Tags: paris
finally
attack
prompts
AstraZeneca And Isis Pharmaceuticals To Discover And Develop Antisense Drugs For Cardiovascular, Metabolic And Renal Diseases
2015-08-04 03:27:28| drugdiscoveryonline News Articles
Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) and AstraZeneca today announced a strategic collaboration to discover and develop antisense therapies for cardiovascular, metabolic and renal diseases.
Tags: develop
discover
drugs
diseases
ISIS Pharmaceuticals: Another Entry Point
2015-07-28 21:37:55| Chemicals - Topix.net
Like most biotech companies with little-to-no product revenue stream, the stock is quite volatile and driven largely by news flow. The company also benefits from several large pharmaceutical partners including J&J, Biogen Idec, Glaxo Smith Kline, Bayer, and Astra Zeneca.
Tags: point
entry
pharmaceuticals
isis
Isis Pharmaceuticals forms Cambridge subsidiary, plans to hire 20
2015-01-06 19:20:39| Biotech - Topix.net
California biotech Isis Pharmaceuticals , known for its drugs for rare and cardiovascular diseases using RNA-based technology, is forming a Cambridge subsidiary to further development of its drugs to control fat and cholesterol in the blood. Akcea Therapeutics is being called the "lipid franchise" of Carlsbad, Calif.-based Isis in a statement today, to be headed by former Genzyme Corp. and Moderna Therapeutics executive Paula Soteropoulos .
Tags: plans
forms
hire
cambridge